董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joseph C. Galante | 男 | Independent Director | 76 | 6.98万美元 | 6.19 | 2026-04-21 |
| Caroline R. Young | 女 | Independent Director | 52 | 6.98万美元 | 3.33 | 2026-04-21 |
| Kenneth J. Krogulski | 男 | Independent Director | 68 | 8.70万美元 | 29.65 | 2026-04-21 |
| Martin S. Brown, Jr. | 男 | Independent Director | 61 | 未披露 | 未持股 | 2026-04-21 |
| James R. Jones | 男 | Independent Director | 78 | 6.88万美元 | 4.51 | 2026-04-21 |
| A.J. Kazimi | 男 | Chairman,Chief Executive Officer and Director | 67 | 155.88万美元 | 578.92 | 2026-04-21 |
| Gordon R. Bernard | 男 | Independent Director | 74 | 9.90万美元 | 未持股 | 2026-04-21 |
| Martin S. Brown, Jr. | 男 | Independent Director | 62 | 5.88万美元 | 0.85 | 2026-04-21 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John M. Hamm | 男 | Chief Financial Officer and Vice President | 70 | 31.24万美元 | 2.31 | 2026-04-21 |
| Chris T. Bitterman | 男 | Vice President Sales and Marketing | 60 | 33.78万美元 | 0.67 | 2026-04-21 |
| Todd M. Anthony | 男 | Vice President Organizational Development | 64 | 35.56万美元 | 1.93 | 2026-04-21 |
| A.J. Kazimi | 男 | Chairman,Chief Executive Officer and Director | 67 | 155.88万美元 | 578.92 | 2026-04-21 |
| James L. Herman | 男 | Vice President Trade and Distribution | 70 | 22.47万美元 | 4.13 | 2026-04-21 |
董事简历
中英对照 | 中文 | 英文- Joseph C. Galante
-
Joseph C. Galante从1995年1月直到2010年7月退休担任索尼音乐（Sony Music）的董事会主席。他帮助阿拉巴马、柯林布雷克、肯尼·切斯尼、萨拉·埃文斯、戴夫·马休斯、武当派、SWV、贾德氏、孤星合唱团、玛蒂娜·麦克布莱德、K.T. Oslin、凯丽·皮克勒、凯莉·安德伍德、凯斯惠特利、克里斯杨和众多其他歌手开启演艺事业。他的领导力为诸如布鲁克斯和邓恩组合、艾伦·杰克逊、米兰达·兰伯特和布拉德·派斯利等超级明星的演艺事业提供了支撑。他担任美国乡村音乐协会（Country Music Association）、易洛魁资本（Iroquois Capital）、Artist Growth和Fishbowl Spirits的董事。他目前担任纳什维尔企业家中心的常驻导师。
Joseph C. Galante became a member of Board of Directors in 2018. He is a mic indtry executive with extensive experience that spans a celebrated career. He is accredited with developing the careers of Alabama, Dave Mathews Band, Dolly Parton, Kenny Chesney, Brad Paisley, Martina McBride, Carrie Underwood, Clint Black, Miranda Lambert, and the Judds, among others. Mr. Galante began at RCA Records in New York, follod by a transfer to RCA Nashville where he served as a director at the label, follod by the role of Vice President of Promotion and Marketing. At the age of 32 he became the youngest person ever named to run a major country record label. In 1990 he was appointed President of RCA Records based in New York. He returned to Nashville as Chairman to run the RCA and BNA labels in Nashville. Under his leadership, RCA Records was the number one country label for eleven consecutive years. He then served as Chairman of Sony Mic Nashville for six years. He was presented with the Bob Kingsley Living Legend Award by the Opry Trt to honor his work for country mic. In 2022, Mr. Galante was given the esteemed honor of being inducted into the Country Mic Hall of Fame. Mr. Galante currently serves on the board of the Country Mic Association Foundation. - Joseph C. Galante从1995年1月直到2010年7月退休担任索尼音乐（Sony Music）的董事会主席。他帮助阿拉巴马、柯林布雷克、肯尼·切斯尼、萨拉·埃文斯、戴夫·马休斯、武当派、SWV、贾德氏、孤星合唱团、玛蒂娜·麦克布莱德、K.T. Oslin、凯丽·皮克勒、凯莉·安德伍德、凯斯惠特利、克里斯杨和众多其他歌手开启演艺事业。他的领导力为诸如布鲁克斯和邓恩组合、艾伦·杰克逊、米兰达·兰伯特和布拉德·派斯利等超级明星的演艺事业提供了支撑。他担任美国乡村音乐协会（Country Music Association）、易洛魁资本（Iroquois Capital）、Artist Growth和Fishbowl Spirits的董事。他目前担任纳什维尔企业家中心的常驻导师。
- Joseph C. Galante became a member of Board of Directors in 2018. He is a mic indtry executive with extensive experience that spans a celebrated career. He is accredited with developing the careers of Alabama, Dave Mathews Band, Dolly Parton, Kenny Chesney, Brad Paisley, Martina McBride, Carrie Underwood, Clint Black, Miranda Lambert, and the Judds, among others. Mr. Galante began at RCA Records in New York, follod by a transfer to RCA Nashville where he served as a director at the label, follod by the role of Vice President of Promotion and Marketing. At the age of 32 he became the youngest person ever named to run a major country record label. In 1990 he was appointed President of RCA Records based in New York. He returned to Nashville as Chairman to run the RCA and BNA labels in Nashville. Under his leadership, RCA Records was the number one country label for eleven consecutive years. He then served as Chairman of Sony Mic Nashville for six years. He was presented with the Bob Kingsley Living Legend Award by the Opry Trt to honor his work for country mic. In 2022, Mr. Galante was given the esteemed honor of being inducted into the Country Mic Hall of Fame. Mr. Galante currently serves on the board of the Country Mic Association Foundation.
- Caroline R. Young
-
CarolineR.Young于2016年加入坎伯兰药业董事会。她此前曾担任the Nashville Health Care Council的总裁（从2008年到2015年）。在她的领导下，该委员会的成员已扩大到300多个不同的组织，并发起了一项旨在提高企业高管技能的独一无二的研究员计划。此外，该委员会的创新领导力医疗保健计划扩大到1000名成员。Young女士于2004年加入理事会，担任Vice President。在理事会之前，Young女士从2002年到2004年是Life Science Tennessee的创始执行董事。从1998年到2002年，她还担任田纳西州经济和社区发展部的通信职位。Young女士最近担任NashvilleHealth的执行董事，这是一项专注于改善Nashville-Davidson县公民健康的倡议。NashvilleHealth致力于解决地区健康平等问题，并确保Nashville继续成为一个很好的生活和工作场所。《纳什维尔商业日报》（Nashville Business Journal）和《纳什维尔医学新闻》（Nashville Medical News）分别将杨女士评为“梦百合英雄”和“值得关注的女性”。目前，杨女士是总部位于华盛顿特区的美国梦百合行业女性商界领袖顾问委员会的成员。Young女士拥有密西西比大学（University of Mississippi）的学士学位和田纳西大学（University of Tennessee）的硕士学位。
Caroline R. Young joined Board of Directors in 2016. Currently, she serves as Head of Partnership Development at Frist Cressey Ventures, where she foces on accelerating value for their partnerships and enhancing relationships with indtry wide stakeholders. Previoly Ms. Young partnered with Former U.S. Senate Majority Leader Bill Frist to launch NashvilleHealth, a first of a kind initiative to reduce disparities and drive community level health improvement. Prior to that role, Caroline led one of the nation's premier health care indtry associations, the Nashville Health Care Council, where she cultivated a national network of executives in support of indtry leadership and innovation. She also held prior positions as the founding Executive Director of Life Sciences Tennessee and Director of Communications and Advertising at the State of Tennessee's Department of Economic and Community Development. Ms. Young holds an M.S. from the University of Tennessee and a B.A. from the University of Mississippi. - CarolineR.Young于2016年加入坎伯兰药业董事会。她此前曾担任the Nashville Health Care Council的总裁（从2008年到2015年）。在她的领导下，该委员会的成员已扩大到300多个不同的组织，并发起了一项旨在提高企业高管技能的独一无二的研究员计划。此外，该委员会的创新领导力医疗保健计划扩大到1000名成员。Young女士于2004年加入理事会，担任Vice President。在理事会之前，Young女士从2002年到2004年是Life Science Tennessee的创始执行董事。从1998年到2002年，她还担任田纳西州经济和社区发展部的通信职位。Young女士最近担任NashvilleHealth的执行董事，这是一项专注于改善Nashville-Davidson县公民健康的倡议。NashvilleHealth致力于解决地区健康平等问题，并确保Nashville继续成为一个很好的生活和工作场所。《纳什维尔商业日报》（Nashville Business Journal）和《纳什维尔医学新闻》（Nashville Medical News）分别将杨女士评为“梦百合英雄”和“值得关注的女性”。目前，杨女士是总部位于华盛顿特区的美国梦百合行业女性商界领袖顾问委员会的成员。Young女士拥有密西西比大学（University of Mississippi）的学士学位和田纳西大学（University of Tennessee）的硕士学位。
- Caroline R. Young joined Board of Directors in 2016. Currently, she serves as Head of Partnership Development at Frist Cressey Ventures, where she foces on accelerating value for their partnerships and enhancing relationships with indtry wide stakeholders. Previoly Ms. Young partnered with Former U.S. Senate Majority Leader Bill Frist to launch NashvilleHealth, a first of a kind initiative to reduce disparities and drive community level health improvement. Prior to that role, Caroline led one of the nation's premier health care indtry associations, the Nashville Health Care Council, where she cultivated a national network of executives in support of indtry leadership and innovation. She also held prior positions as the founding Executive Director of Life Sciences Tennessee and Director of Communications and Advertising at the State of Tennessee's Department of Economic and Community Development. Ms. Young holds an M.S. from the University of Tennessee and a B.A. from the University of Mississippi.
- Kenneth J. Krogulski
-
KennethJ.Krogulski于2017年加入坎伯兰董事会。他拥有40年以上的证券分析和投资组合管理经验，目前担任Berkshire Asset Management，LLC的总裁兼首席执行官，以及公司的首席投资官。伯克希尔是一家拥有33年历史的独立证券交易委员会注册的宾夕法尼亚州投资咨询公司，在监管下拥有超过22亿美元的资产。在Berkshire之前，Krogulski先生于1979年在First Eastern Bank，N.A.（现为PNC Financial）开始了他的金融服务职业生涯，担任投资分析师和投资组合经理，在那里他晋升为信托部首席投资官。他随后于1990年加入Berkshire公司，随后领导管理层收购Legg Mason公司。在他的领导下，伯克希尔在监管下的资产从2006年的6亿美元增长到现在的超过22亿美元。目前，Krogulski先生任职于Allied Services Rehabilitation Hospital的董事会，是Landmark Community Bank LDKB:NASDAQ的董事。此前，他曾担任the Wyoming Valley Health Care System、the F.M.Kirby Center for the Performing Arts、the Luzerne Foundation和其他各种社区委员会的董事。Krogulski先生拥有宾夕法尼亚印第安纳大学（Indiana University of Pennsylvania）的金融学学士学位，并在威尔克斯大学（Wilkes University）获得工商管理硕士学位。此外，他持有特许金融分析师称号。
Kenneth J. Krogulski joined Cumberland's Board of Directors in 2017. He has 47 years of experience in security analysis and portfolio management and is currently the Managing Partner and Chief Investment Officer of Berkshire Asset Management, LLC, an independent SEC registered investment advisory firm. Prior to Berkshire, Mr. Krogulski began his career in financial services at First Eastern Bank, N.A., now PNC Financial, where he advanced to Chief Investment Officer of their Trt Department. Mr. Krogulski is currently on the Board of Allied Services Integrated Health System. He previoly served as a Director of Landmark Community Bank (LDKB: NASDAQ) and numero nonprofit organizations. Mr. Krogulski holds a B.S. in finance from Indiana University of Pennsylvania and earned his M.B.A. from Wilkes University. In addition, he holds the Chartered Financial Analyst designation. - KennethJ.Krogulski于2017年加入坎伯兰董事会。他拥有40年以上的证券分析和投资组合管理经验，目前担任Berkshire Asset Management，LLC的总裁兼首席执行官，以及公司的首席投资官。伯克希尔是一家拥有33年历史的独立证券交易委员会注册的宾夕法尼亚州投资咨询公司，在监管下拥有超过22亿美元的资产。在Berkshire之前，Krogulski先生于1979年在First Eastern Bank，N.A.（现为PNC Financial）开始了他的金融服务职业生涯，担任投资分析师和投资组合经理，在那里他晋升为信托部首席投资官。他随后于1990年加入Berkshire公司，随后领导管理层收购Legg Mason公司。在他的领导下，伯克希尔在监管下的资产从2006年的6亿美元增长到现在的超过22亿美元。目前，Krogulski先生任职于Allied Services Rehabilitation Hospital的董事会，是Landmark Community Bank LDKB:NASDAQ的董事。此前，他曾担任the Wyoming Valley Health Care System、the F.M.Kirby Center for the Performing Arts、the Luzerne Foundation和其他各种社区委员会的董事。Krogulski先生拥有宾夕法尼亚印第安纳大学（Indiana University of Pennsylvania）的金融学学士学位，并在威尔克斯大学（Wilkes University）获得工商管理硕士学位。此外，他持有特许金融分析师称号。
- Kenneth J. Krogulski joined Cumberland's Board of Directors in 2017. He has 47 years of experience in security analysis and portfolio management and is currently the Managing Partner and Chief Investment Officer of Berkshire Asset Management, LLC, an independent SEC registered investment advisory firm. Prior to Berkshire, Mr. Krogulski began his career in financial services at First Eastern Bank, N.A., now PNC Financial, where he advanced to Chief Investment Officer of their Trt Department. Mr. Krogulski is currently on the Board of Allied Services Integrated Health System. He previoly served as a Director of Landmark Community Bank (LDKB: NASDAQ) and numero nonprofit organizations. Mr. Krogulski holds a B.S. in finance from Indiana University of Pennsylvania and earned his M.B.A. from Wilkes University. In addition, he holds the Chartered Financial Analyst designation.
- Martin S. Brown, Jr.
-
Martin S. Brown，Jr.自2022年起担任董事会成员。He previoly在Brown Forman的董事会任职十年，该公司是一家纽约证券交易所上市公司。三十多年来，布朗先生还在纳什维尔的Adams and Reese，LLP及其前身公司担任执业律师。Adams and Reese是一家多州律师事务所，在10个州拥有超过325名律师。他的客户主要是私人持有的binesses及其所有者。他曾入选最佳律师自2009年以来公司法类别的国家同行评审指南。自2018年以来，他一直担任Aegis Sciences Corporation母公司的董事会成员，该公司是一家获得广泛认可的法医毒理学实验室。布朗先生还担任过许多社区组织的董事会成员或官员，包括田纳西州土地TRT、纳什维尔公共广播电台、蒙哥马利贝尔学院、纳什维尔公共电视台、森特斯通心理健康中心、奇克伍德庄园和花园，以及大自然保护协会田纳西州分会。他是纳什维尔经济俱乐部和纳什维尔资本网络的成员。布朗先生在耶鲁大学获得本科学位后，获得了范德比尔特大学的法律学位。
Martin S. Brown, Jr. has served on Board of Directors since 2022. He previoly served for ten years on the Board of Directors of Brown Forman, which is a New York Stock Exchange listed company. For more than thirty years, Mr. Brown has also been a practicing attorney in Nashville with Adams and Reese, LLP, and its predecessor firm. Adams and Reese is a multi state law firm with more than 325 attorneys over 10 states. His clients primarily are privately held binesses and their owners. He has been listed in Best Lawyers national peer review guide in the corporate law category since 2009. Since 2018 he has served on the Board of Directors of the parent company of Aegis Sciences Corporation, a widely accredited forensic toxicology laboratory. Mr. Brown also has served as a board member or officer for many community organizations, including the Land Trt for Tennessee, Nashville Public Radio, Montgomery Bell Academy, Nashville Public Television, Centerstone Mental Health Center, Cheekwood Estate and Gardens, and the Tennessee chapter of the Nature Conservancy. He is a member of the Economic Club of Nashville and the Nashville Capital Network. Mr. Brown earned his law degree from Vanderbilt University after receiving his undergraduate degree from Yale University. - Martin S. Brown，Jr.自2022年起担任董事会成员。He previoly在Brown Forman的董事会任职十年，该公司是一家纽约证券交易所上市公司。三十多年来，布朗先生还在纳什维尔的Adams and Reese，LLP及其前身公司担任执业律师。Adams and Reese是一家多州律师事务所，在10个州拥有超过325名律师。他的客户主要是私人持有的binesses及其所有者。他曾入选最佳律师自2009年以来公司法类别的国家同行评审指南。自2018年以来，他一直担任Aegis Sciences Corporation母公司的董事会成员，该公司是一家获得广泛认可的法医毒理学实验室。布朗先生还担任过许多社区组织的董事会成员或官员，包括田纳西州土地TRT、纳什维尔公共广播电台、蒙哥马利贝尔学院、纳什维尔公共电视台、森特斯通心理健康中心、奇克伍德庄园和花园，以及大自然保护协会田纳西州分会。他是纳什维尔经济俱乐部和纳什维尔资本网络的成员。布朗先生在耶鲁大学获得本科学位后，获得了范德比尔特大学的法律学位。
- Martin S. Brown, Jr. has served on Board of Directors since 2022. He previoly served for ten years on the Board of Directors of Brown Forman, which is a New York Stock Exchange listed company. For more than thirty years, Mr. Brown has also been a practicing attorney in Nashville with Adams and Reese, LLP, and its predecessor firm. Adams and Reese is a multi state law firm with more than 325 attorneys over 10 states. His clients primarily are privately held binesses and their owners. He has been listed in Best Lawyers national peer review guide in the corporate law category since 2009. Since 2018 he has served on the Board of Directors of the parent company of Aegis Sciences Corporation, a widely accredited forensic toxicology laboratory. Mr. Brown also has served as a board member or officer for many community organizations, including the Land Trt for Tennessee, Nashville Public Radio, Montgomery Bell Academy, Nashville Public Television, Centerstone Mental Health Center, Cheekwood Estate and Gardens, and the Tennessee chapter of the Nature Conservancy. He is a member of the Economic Club of Nashville and the Nashville Capital Network. Mr. Brown earned his law degree from Vanderbilt University after receiving his undergraduate degree from Yale University.
- James R. Jones
-
James R. Jones自2010年起一直担任我们的董事会成员。在毕马威会计师事务所作为专业会计度过了35年的职业生涯，包括从1999年到2006年担任在田纳西州纳什维尔办公室的管理合伙人。他曾在毕马威担任各种职位，其中包括在杰克逊、密西西比、华盛顿特区和格林维尔、南卡罗来纳州的办公室。任职于毕马威会计师事务所期间，率领100多人向庞大客户群提供会计服务。2006年退休之后，曾担任顾问，并提供给多家公司各种咨询服务，包括管理长期护理机构的董事会和担任慈善机构的临时行政总裁。他是在范德堡大学欧文研究生院的一位兼职教师。目前，他是田纳西Argent Trust Company的董事和审核委员会委员。亦担任本公司审核委员会主席，和委员会的财务专家。持有密西西比学院的理学士学位和密西西比州立大学的工商管理硕士学位。
James R. Jones has served as a member of Board of Directors since 2010. Mr. Jones' 36 year career in professional accounting at KPMG LLP included the role of Managing Partner at their Nashville, Tennessee office from 1999 to 2006. He served in vario capacities during his career at KPMG which also included positions at their offices in Jackson, Mississippi, Washington, D.C. and Greenville, South Carolina. During his tenure with KPMG, Mr. Jones led a team of more than 100 individuals providing accounting services for an extensive client base. Following retirement in 2006, he has served as an advisor as ll as provided vario consulting services to several companies, including acting as liaison beten management and the board of directors of a long term care facility and serving as interim CEO of a charitable organization. He is currently a board director and member of the audit committees of Argent Trt Company of Tennessee and Belmont University. Mr. Jones also serves as a member of Audit Committee and is Audit Committee financial expert. - James R. Jones自2010年起一直担任我们的董事会成员。在毕马威会计师事务所作为专业会计度过了35年的职业生涯，包括从1999年到2006年担任在田纳西州纳什维尔办公室的管理合伙人。他曾在毕马威担任各种职位，其中包括在杰克逊、密西西比、华盛顿特区和格林维尔、南卡罗来纳州的办公室。任职于毕马威会计师事务所期间，率领100多人向庞大客户群提供会计服务。2006年退休之后，曾担任顾问，并提供给多家公司各种咨询服务，包括管理长期护理机构的董事会和担任慈善机构的临时行政总裁。他是在范德堡大学欧文研究生院的一位兼职教师。目前，他是田纳西Argent Trust Company的董事和审核委员会委员。亦担任本公司审核委员会主席，和委员会的财务专家。持有密西西比学院的理学士学位和密西西比州立大学的工商管理硕士学位。
- James R. Jones has served as a member of Board of Directors since 2010. Mr. Jones' 36 year career in professional accounting at KPMG LLP included the role of Managing Partner at their Nashville, Tennessee office from 1999 to 2006. He served in vario capacities during his career at KPMG which also included positions at their offices in Jackson, Mississippi, Washington, D.C. and Greenville, South Carolina. During his tenure with KPMG, Mr. Jones led a team of more than 100 individuals providing accounting services for an extensive client base. Following retirement in 2006, he has served as an advisor as ll as provided vario consulting services to several companies, including acting as liaison beten management and the board of directors of a long term care facility and serving as interim CEO of a charitable organization. He is currently a board director and member of the audit committees of Argent Trt Company of Tennessee and Belmont University. Mr. Jones also serves as a member of Audit Committee and is Audit Committee financial expert.
- A.J. Kazimi
-
A.J. Kazimi于1999年创办本公司。自成立以来，一直担任公司董事会主席及行政总裁。他的职业生涯包括在生物制药行业的25年。在加入本公司前，帮助创立Therapeutic Antibodies Inc.（一家国际生物制药公司），长达11年。作为总裁兼首席运营官，从公司的起步到首次公开募股，他为公司的增长做出了突出的贡献。 监督三个国家的业务，亲自参与公司的产品开发战略、批准、许可协议和超过1亿美元的股权和债务融资筹集。在这之前，曾在Brown-Forman公司担任一系列的管理职位，并帮助推出多款新产品。 曾服务于纳什维尔保健委员会（美国最大医疗保健公司的行业协会）和Aegis Toxicology Sciences公司（由联邦政府认证的法医毒物实验室）的董事会。他还担任CET的主席及行政总裁。
A.J. Kazimi is the Chairman of Board of Directors and Chief Executive Officer who founded Cumberland in 1999. His career includes over 30 years in the biopharmaceutical indtry. At Cumberland, he has overseen the development and FDA approval of key Company brands, while also leading the acquisition of the Company's other commercial products. He was responsible for Cumberland's initial public offering and listing on the NASDAQ stock exchange. Mr. Kazimi also serves as Chairman and Chief Executive of Cumberland Emerging Technologies, a joint initiative with Vanderbilt University and the state of Tennessee, designed to support the development of early stage life sciences programs and companies. Prior to joining Cumberland, he spent eleven years helping to build Therapeutic Antibodies Inc., an international biopharmaceutical company. As President and Chief Operating Officer, he made key contributions to that company's growth from its start up phase through its initial public offering and listing on the London stock exchange. Mr. Kazimi started his career at Brown Forman Corporation, rising through a series of management positions. He is Chairman of the Board for the Gettysburg Foundation which partners with the National Park Service to preserve that historic military park. He is also a member of the Board of the Tennessee Historical Society. He previoly served on the Board of Directors for the Nashville Health Care Council, an association of the largest concentration of healthcare companies in the U.S. and the Board of Aegis Sciences Corporation, a federally certified forensic toxicology laboratory, which has sold twice to large private equity investors. - A.J. Kazimi于1999年创办本公司。自成立以来，一直担任公司董事会主席及行政总裁。他的职业生涯包括在生物制药行业的25年。在加入本公司前，帮助创立Therapeutic Antibodies Inc.（一家国际生物制药公司），长达11年。作为总裁兼首席运营官，从公司的起步到首次公开募股，他为公司的增长做出了突出的贡献。 监督三个国家的业务，亲自参与公司的产品开发战略、批准、许可协议和超过1亿美元的股权和债务融资筹集。在这之前，曾在Brown-Forman公司担任一系列的管理职位，并帮助推出多款新产品。 曾服务于纳什维尔保健委员会（美国最大医疗保健公司的行业协会）和Aegis Toxicology Sciences公司（由联邦政府认证的法医毒物实验室）的董事会。他还担任CET的主席及行政总裁。
- A.J. Kazimi is the Chairman of Board of Directors and Chief Executive Officer who founded Cumberland in 1999. His career includes over 30 years in the biopharmaceutical indtry. At Cumberland, he has overseen the development and FDA approval of key Company brands, while also leading the acquisition of the Company's other commercial products. He was responsible for Cumberland's initial public offering and listing on the NASDAQ stock exchange. Mr. Kazimi also serves as Chairman and Chief Executive of Cumberland Emerging Technologies, a joint initiative with Vanderbilt University and the state of Tennessee, designed to support the development of early stage life sciences programs and companies. Prior to joining Cumberland, he spent eleven years helping to build Therapeutic Antibodies Inc., an international biopharmaceutical company. As President and Chief Operating Officer, he made key contributions to that company's growth from its start up phase through its initial public offering and listing on the London stock exchange. Mr. Kazimi started his career at Brown Forman Corporation, rising through a series of management positions. He is Chairman of the Board for the Gettysburg Foundation which partners with the National Park Service to preserve that historic military park. He is also a member of the Board of the Tennessee Historical Society. He previoly served on the Board of Directors for the Nashville Health Care Council, an association of the largest concentration of healthcare companies in the U.S. and the Board of Aegis Sciences Corporation, a federally certified forensic toxicology laboratory, which has sold twice to large private equity investors.
- Gordon R. Bernard
-
Gordon R. Bernard 自1999年至2010年担任我们的医疗总监，目前担任公司的顾问和医学顾问委员会主席。自2010年以来，一直担任我们的董事。他是范德比尔特大学的负责研究的协理副校长，也是医学Melinda Owen Bass Professor，过敏科、肺科和重病急救科的前任主任。此外，他是临床科学的高级副院长和范德比尔特的药房和治疗委员会的主席，负责审批批准范德比尔特医学中心的药物和治疗。自1980年以来，一直从事国家和国际的药品临床试验。自1994年成立以来，一直担任美国国立卫生研究院急性呼吸窘迫综合征临床试验网络的委员会的主席。这个网络是唯一得到联邦政府支持的，在医院的重症监护病房或加护病房进行持续性系统性的研究。持有西南路易斯安那大学的理学士学位和路易斯安那州立大学的医学博士学位。在范德比尔特的重症监护室工作， 第一手观察管理周围各种最严重患者的护理药品问题，并了解其未满足的医疗需求。
Gordon R. Bernard served as Medical Director from 1999 until 2010 and currently serves as Chair of Medical Advisory Board. He has served on Board of Directors since 2010. Dr. Bernard is currently the Melinda On Bass Professor of Medicine and former Chief of the Division for Allergy, Pulmonary & Critical Care Medicine for Vanderbilt University Medical Center (VUMC). In addition, he was formerly the Executive Vice President for Research at VUMC and former Chairman of VUMC's Pharmacy, Therapeutics and Diagnostics Committee, which is responsible for approving their formulary of approved drugs and therapeutics. Dr. Bernard has been conducting national and international trials of pharmaceuticals since 1980 and has been the Steering Committee Chair of the National Institutes of Health, Acute Respiratory Distress Syndrome Clinical Trials Network since its inception in 1994 through its conclion in 2014. This Network is one of the few federally supported ongoing systems for the conduct of research in the hospital Intensive Care Unit. He holds a B.S. from the University of Southstern Louisiana and an M.D. from Louisiana State University. - Gordon R. Bernard 自1999年至2010年担任我们的医疗总监，目前担任公司的顾问和医学顾问委员会主席。自2010年以来，一直担任我们的董事。他是范德比尔特大学的负责研究的协理副校长，也是医学Melinda Owen Bass Professor，过敏科、肺科和重病急救科的前任主任。此外，他是临床科学的高级副院长和范德比尔特的药房和治疗委员会的主席，负责审批批准范德比尔特医学中心的药物和治疗。自1980年以来，一直从事国家和国际的药品临床试验。自1994年成立以来，一直担任美国国立卫生研究院急性呼吸窘迫综合征临床试验网络的委员会的主席。这个网络是唯一得到联邦政府支持的，在医院的重症监护病房或加护病房进行持续性系统性的研究。持有西南路易斯安那大学的理学士学位和路易斯安那州立大学的医学博士学位。在范德比尔特的重症监护室工作， 第一手观察管理周围各种最严重患者的护理药品问题，并了解其未满足的医疗需求。
- Gordon R. Bernard served as Medical Director from 1999 until 2010 and currently serves as Chair of Medical Advisory Board. He has served on Board of Directors since 2010. Dr. Bernard is currently the Melinda On Bass Professor of Medicine and former Chief of the Division for Allergy, Pulmonary & Critical Care Medicine for Vanderbilt University Medical Center (VUMC). In addition, he was formerly the Executive Vice President for Research at VUMC and former Chairman of VUMC's Pharmacy, Therapeutics and Diagnostics Committee, which is responsible for approving their formulary of approved drugs and therapeutics. Dr. Bernard has been conducting national and international trials of pharmaceuticals since 1980 and has been the Steering Committee Chair of the National Institutes of Health, Acute Respiratory Distress Syndrome Clinical Trials Network since its inception in 1994 through its conclion in 2014. This Network is one of the few federally supported ongoing systems for the conduct of research in the hospital Intensive Care Unit. He holds a B.S. from the University of Southstern Louisiana and an M.D. from Louisiana State University.
- Martin S. Brown, Jr.
-
Martin S. Brown, Jr.，2005年起，他担任Adams and Reese LLP的律师；1999至2005年，担任Adams and Reese LLP的前身Stokes & Bartholomew, P.A的律师。
Martin S. Brown, Jr. has served on Board of Directors since 2022. He previoly served for ten years on the Board of Directors of Brown Forman, which is a New York Stock Exchange listed company. For more than thirty years, Mr. Brown has also been a practicing attorney in Nashville with Adams and Reese, LLP, and its predecessor firm. Adams and Reese is a multi state law firm with more than 325 attorneys over 10 states. His clients primarily are privately held binesses and their owners. He has been listed in Best Lawyers national peer review guide in the corporate law category since 2009. Since 2018 he has served on the Board of Directors of the parent company of Aegis Sciences Corporation, a widely accredited forensic toxicology laboratory. Mr. Brown also has served as a board member or officer for many community organizations, including the Land Trt for Tennessee, Nashville Public Radio, Montgomery Bell Academy, Nashville Public Television, Centerstone Mental Health Center, Cheekwood Estate and Gardens, and the Tennessee chapter of the Nature Conservancy. He is a member of the Economic Club of Nashville and the Nashville Capital Network. Mr. Brown earned his law degree from Vanderbilt University after receiving his undergraduate degree from Yale University. - Martin S. Brown, Jr.，2005年起，他担任Adams and Reese LLP的律师；1999至2005年，担任Adams and Reese LLP的前身Stokes & Bartholomew, P.A的律师。
- Martin S. Brown, Jr. has served on Board of Directors since 2022. He previoly served for ten years on the Board of Directors of Brown Forman, which is a New York Stock Exchange listed company. For more than thirty years, Mr. Brown has also been a practicing attorney in Nashville with Adams and Reese, LLP, and its predecessor firm. Adams and Reese is a multi state law firm with more than 325 attorneys over 10 states. His clients primarily are privately held binesses and their owners. He has been listed in Best Lawyers national peer review guide in the corporate law category since 2009. Since 2018 he has served on the Board of Directors of the parent company of Aegis Sciences Corporation, a widely accredited forensic toxicology laboratory. Mr. Brown also has served as a board member or officer for many community organizations, including the Land Trt for Tennessee, Nashville Public Radio, Montgomery Bell Academy, Nashville Public Television, Centerstone Mental Health Center, Cheekwood Estate and Gardens, and the Tennessee chapter of the Nature Conservancy. He is a member of the Economic Club of Nashville and the Nashville Capital Network. Mr. Brown earned his law degree from Vanderbilt University after receiving his undergraduate degree from Yale University.
高管简历
中英对照 | 中文 | 英文- John M. Hamm
约翰·哈姆（John M. Hamm）负责坎伯兰郡的金融系统，并负责报告工作。他还负责监督公司的BINES开发和法律活动。Hamm先生在多个行业拥有超过25年的财务、会计和运营经验，其中大部分在医疗保健领域。He previoly曾在HealthSpring，Inc.担任药房首席运营官和首席财务官等职位，该公司是一家管理式医疗机构，目前以信诺 HealthSpring的名义运营。在此之前，他是Emdeon Biness Services的财务副总裁。现在以Change Healthcare Inc.名义运营的医疗保健技术公司爱得昂，是一家纳斯达克上市公司，年收入超30亿美元。
John M. Hamm is responsible for Cumberland's financial systems, and reporting. He also oversees the Company's biness development and legal activities. Mr. Hamm has over 25 years of finance, accounting and operations experience in several indtries, with a majority in health care. He previoly held the positions of Chief Operating Officer and Chief Financial Officer, Pharmacy at HealthSpring, Inc., a managed care organization currently operating as Cigna HealthSpring. Prior to that he was Vice President Finance at Emdeon Biness Services. Emdeon Inc., a healthcare technology firm that now operates as Change Healthcare Inc., is a NASDAQ listed company with over $3 billion in annual revenue.- 约翰·哈姆（John M. Hamm）负责坎伯兰郡的金融系统，并负责报告工作。他还负责监督公司的BINES开发和法律活动。Hamm先生在多个行业拥有超过25年的财务、会计和运营经验，其中大部分在医疗保健领域。He previoly曾在HealthSpring，Inc.担任药房首席运营官和首席财务官等职位，该公司是一家管理式医疗机构，目前以信诺 HealthSpring的名义运营。在此之前，他是Emdeon Biness Services的财务副总裁。现在以Change Healthcare Inc.名义运营的医疗保健技术公司爱得昂，是一家纳斯达克上市公司，年收入超30亿美元。
- John M. Hamm is responsible for Cumberland's financial systems, and reporting. He also oversees the Company's biness development and legal activities. Mr. Hamm has over 25 years of finance, accounting and operations experience in several indtries, with a majority in health care. He previoly held the positions of Chief Operating Officer and Chief Financial Officer, Pharmacy at HealthSpring, Inc., a managed care organization currently operating as Cigna HealthSpring. Prior to that he was Vice President Finance at Emdeon Biness Services. Emdeon Inc., a healthcare technology firm that now operates as Change Healthcare Inc., is a NASDAQ listed company with over $3 billion in annual revenue.
- Chris T. Bitterman
Chris T. Bitterman加入坎伯兰大学，此前他在急性护理和药品销售管理领域拥有30多年的杰出职业生涯。亮点包括担任Lupin Pharmaceuticals、Daiichi Sankyo的全国销售总监以及赛诺菲 Aventis的区域销售总监，这些公司都是药品制造公司。在坎伯兰，Bitterman先生最初担任医院销售总监，领导医院销售部门。Bitterman先生的角色随后扩大到包括肿瘤学Biness，他被提升为医院和肿瘤销售高级总监。目前，Bitterman先生担任销售和营销副总裁，负责领导坎伯兰商业投资组合的国民账户、销售和营销工作，并实现年度财务目标。
Chris T. Bitterman joined Cumberland following a distinguished career in Acute Care and pharmaceutical sales management spanning over 30 years. Highlights include his roles as National Sales Director for Lupin Pharmaceuticals, Daiichi Sankyo and Regional Sales Director for Sanofi Aventis, all of which are pharmaceutical manufacturing companies. At Cumberland, Mr. Bitterman first served as the Hospital Sales Director, leading the Hospital Sales division. Mr. Bitterman's role then expanded to include the Oncology Biness, and he was promoted to Senior Director of Hospital and Oncology Sales. Currently, Mr. Bitterman is the Vice President of Sales & Marketing, where he is responsible for leading the national accounts, sales and marketing efforts for Cumberland's commercial portfolio and delivering annual financial objectives.- Chris T. Bitterman加入坎伯兰大学，此前他在急性护理和药品销售管理领域拥有30多年的杰出职业生涯。亮点包括担任Lupin Pharmaceuticals、Daiichi Sankyo的全国销售总监以及赛诺菲 Aventis的区域销售总监，这些公司都是药品制造公司。在坎伯兰，Bitterman先生最初担任医院销售总监，领导医院销售部门。Bitterman先生的角色随后扩大到包括肿瘤学Biness，他被提升为医院和肿瘤销售高级总监。目前，Bitterman先生担任销售和营销副总裁，负责领导坎伯兰商业投资组合的国民账户、销售和营销工作，并实现年度财务目标。
- Chris T. Bitterman joined Cumberland following a distinguished career in Acute Care and pharmaceutical sales management spanning over 30 years. Highlights include his roles as National Sales Director for Lupin Pharmaceuticals, Daiichi Sankyo and Regional Sales Director for Sanofi Aventis, all of which are pharmaceutical manufacturing companies. At Cumberland, Mr. Bitterman first served as the Hospital Sales Director, leading the Hospital Sales division. Mr. Bitterman's role then expanded to include the Oncology Biness, and he was promoted to Senior Director of Hospital and Oncology Sales. Currently, Mr. Bitterman is the Vice President of Sales & Marketing, where he is responsible for leading the national accounts, sales and marketing efforts for Cumberland's commercial portfolio and delivering annual financial objectives.
- Todd M. Anthony
Todd M. Anthony管理人力资源、信息技术和网络安全、组织发展和办公室管理活动。安东尼先生自2010年以来一直在坎伯兰郡工作。在他的任期内，他为培训和发展举措做出了许多贡献，就像人类活动一样。其中包括为每个品牌产品开发和实施销售培训课程。在他的领导下，坎伯兰学院成立，其核心课程和先进的CSE旨在为办公室员工提供工业专业知识和持续学习机会。具有35年药学培训、开发及人力资源管理经验。在加入坎伯兰大学之前，他在Berlex Laboratories Inc.担任过多个职责日益增加的职位，并在该公司工作了19年，该公司在2006年收购先灵公司后现为拜耳医药保健制药公司。
Todd M. Anthony manages human resces, information technology and cybersecurity, organizational development and office administration activities. Mr. Anthony has been with Cumberland since 2010. During his tenure, he has made many contributions to training and development initiatives as ll as human resces activities. These include the development and implementation of a sales training curriculum for each branded product. Under his leadership, the Cumberland Academy was established with a core curriculum and advanced cses designed to provide indtry expertise and continued learning opportunities for the office employees. He has 35 years of pharmaceutical training, development and human resce management experience. Prior to joining Cumberland, he held vario positions of increasing responsibilities at Berlex Laboratories Inc. and spent 19 years at that company which is now Bayer HealthCare Pharmaceuticals following the 2006 acquisition of Schering AG.- Todd M. Anthony管理人力资源、信息技术和网络安全、组织发展和办公室管理活动。安东尼先生自2010年以来一直在坎伯兰郡工作。在他的任期内，他为培训和发展举措做出了许多贡献，就像人类活动一样。其中包括为每个品牌产品开发和实施销售培训课程。在他的领导下，坎伯兰学院成立，其核心课程和先进的CSE旨在为办公室员工提供工业专业知识和持续学习机会。具有35年药学培训、开发及人力资源管理经验。在加入坎伯兰大学之前，他在Berlex Laboratories Inc.担任过多个职责日益增加的职位，并在该公司工作了19年，该公司在2006年收购先灵公司后现为拜耳医药保健制药公司。
- Todd M. Anthony manages human resces, information technology and cybersecurity, organizational development and office administration activities. Mr. Anthony has been with Cumberland since 2010. During his tenure, he has made many contributions to training and development initiatives as ll as human resces activities. These include the development and implementation of a sales training curriculum for each branded product. Under his leadership, the Cumberland Academy was established with a core curriculum and advanced cses designed to provide indtry expertise and continued learning opportunities for the office employees. He has 35 years of pharmaceutical training, development and human resce management experience. Prior to joining Cumberland, he held vario positions of increasing responsibilities at Berlex Laboratories Inc. and spent 19 years at that company which is now Bayer HealthCare Pharmaceuticals following the 2006 acquisition of Schering AG.
- A.J. Kazimi
A.J. Kazimi于1999年创办本公司。自成立以来，一直担任公司董事会主席及行政总裁。他的职业生涯包括在生物制药行业的25年。在加入本公司前，帮助创立Therapeutic Antibodies Inc.（一家国际生物制药公司），长达11年。作为总裁兼首席运营官，从公司的起步到首次公开募股，他为公司的增长做出了突出的贡献。 监督三个国家的业务，亲自参与公司的产品开发战略、批准、许可协议和超过1亿美元的股权和债务融资筹集。在这之前，曾在Brown-Forman公司担任一系列的管理职位，并帮助推出多款新产品。 曾服务于纳什维尔保健委员会（美国最大医疗保健公司的行业协会）和Aegis Toxicology Sciences公司（由联邦政府认证的法医毒物实验室）的董事会。他还担任CET的主席及行政总裁。
A.J. Kazimi is the Chairman of Board of Directors and Chief Executive Officer who founded Cumberland in 1999. His career includes over 30 years in the biopharmaceutical indtry. At Cumberland, he has overseen the development and FDA approval of key Company brands, while also leading the acquisition of the Company's other commercial products. He was responsible for Cumberland's initial public offering and listing on the NASDAQ stock exchange. Mr. Kazimi also serves as Chairman and Chief Executive of Cumberland Emerging Technologies, a joint initiative with Vanderbilt University and the state of Tennessee, designed to support the development of early stage life sciences programs and companies. Prior to joining Cumberland, he spent eleven years helping to build Therapeutic Antibodies Inc., an international biopharmaceutical company. As President and Chief Operating Officer, he made key contributions to that company's growth from its start up phase through its initial public offering and listing on the London stock exchange. Mr. Kazimi started his career at Brown Forman Corporation, rising through a series of management positions. He is Chairman of the Board for the Gettysburg Foundation which partners with the National Park Service to preserve that historic military park. He is also a member of the Board of the Tennessee Historical Society. He previoly served on the Board of Directors for the Nashville Health Care Council, an association of the largest concentration of healthcare companies in the U.S. and the Board of Aegis Sciences Corporation, a federally certified forensic toxicology laboratory, which has sold twice to large private equity investors.- A.J. Kazimi于1999年创办本公司。自成立以来，一直担任公司董事会主席及行政总裁。他的职业生涯包括在生物制药行业的25年。在加入本公司前，帮助创立Therapeutic Antibodies Inc.（一家国际生物制药公司），长达11年。作为总裁兼首席运营官，从公司的起步到首次公开募股，他为公司的增长做出了突出的贡献。 监督三个国家的业务，亲自参与公司的产品开发战略、批准、许可协议和超过1亿美元的股权和债务融资筹集。在这之前，曾在Brown-Forman公司担任一系列的管理职位，并帮助推出多款新产品。 曾服务于纳什维尔保健委员会（美国最大医疗保健公司的行业协会）和Aegis Toxicology Sciences公司（由联邦政府认证的法医毒物实验室）的董事会。他还担任CET的主席及行政总裁。
- A.J. Kazimi is the Chairman of Board of Directors and Chief Executive Officer who founded Cumberland in 1999. His career includes over 30 years in the biopharmaceutical indtry. At Cumberland, he has overseen the development and FDA approval of key Company brands, while also leading the acquisition of the Company's other commercial products. He was responsible for Cumberland's initial public offering and listing on the NASDAQ stock exchange. Mr. Kazimi also serves as Chairman and Chief Executive of Cumberland Emerging Technologies, a joint initiative with Vanderbilt University and the state of Tennessee, designed to support the development of early stage life sciences programs and companies. Prior to joining Cumberland, he spent eleven years helping to build Therapeutic Antibodies Inc., an international biopharmaceutical company. As President and Chief Operating Officer, he made key contributions to that company's growth from its start up phase through its initial public offering and listing on the London stock exchange. Mr. Kazimi started his career at Brown Forman Corporation, rising through a series of management positions. He is Chairman of the Board for the Gettysburg Foundation which partners with the National Park Service to preserve that historic military park. He is also a member of the Board of the Tennessee Historical Society. He previoly served on the Board of Directors for the Nashville Health Care Council, an association of the largest concentration of healthcare companies in the U.S. and the Board of Aegis Sciences Corporation, a federally certified forensic toxicology laboratory, which has sold twice to large private equity investors.
- James L. Herman
James L. Herman处理所有国民经济核算的销售，包括批发和零售连锁企业采购办事处、管理式医疗家庭办公室和联邦政府账户。他还负责监督本公司的合规工作。自2003年以来在本公司工作，有20年的制药行业经验。从1998年到2003年，在Solvay制药公司担任管理式医疗主任和贸易事务与客户服务主任。从1990年至1998年在Schwarz制药担任国民核算和管理式医疗的全国销售领导职务的。持有印第安那大学的理学士学位和Cardinal Stritch大学的工商管理硕士学位。
James L. Herman handles all national accounts sales, including wholesalers and retail chain buying offices, managed care home offices and federal government accounts. He is also charged with overseeing corporate compliance efforts. He has been with since 2003 and has over 30 years of pharmaceutical indtry experience. He previoly served as Director of Managed Care and Director of Trade Affairs and Ctomer Service at Solvay Pharmaceuticals. Prior to that Mr. Herman was with Schwarz Pharma, where he held national sales leadership positions in National Accounts and Managed Care.- James L. Herman处理所有国民经济核算的销售，包括批发和零售连锁企业采购办事处、管理式医疗家庭办公室和联邦政府账户。他还负责监督本公司的合规工作。自2003年以来在本公司工作，有20年的制药行业经验。从1998年到2003年，在Solvay制药公司担任管理式医疗主任和贸易事务与客户服务主任。从1990年至1998年在Schwarz制药担任国民核算和管理式医疗的全国销售领导职务的。持有印第安那大学的理学士学位和Cardinal Stritch大学的工商管理硕士学位。
- James L. Herman handles all national accounts sales, including wholesalers and retail chain buying offices, managed care home offices and federal government accounts. He is also charged with overseeing corporate compliance efforts. He has been with since 2003 and has over 30 years of pharmaceutical indtry experience. He previoly served as Director of Managed Care and Director of Trade Affairs and Ctomer Service at Solvay Pharmaceuticals. Prior to that Mr. Herman was with Schwarz Pharma, where he held national sales leadership positions in National Accounts and Managed Care.